RESUMEN
AIMS: The objective of the study is to assess the efficacy and safety of the novel Magic Touch sirolimus coated-balloon (SCB) when compared to the SeQuent Please Neo paclitaxel coated balloon (PCB) for the treatment of de-novo small vessel coronary artery diseases (SVD). STUDY DESIGN: The TRANSFORM I study is a randomized, multicenter, non-inferiority trial with the intent to enroll a total of 114 patients with a de-novo SVD (≤2.5 mm). Vessel size will be pre-screened by on-line QCA. After successful pre-dilatation without major coronary dissections (type C-F) nor Thrombolysis In Myocardial Infarction trial [TIMI] grade flow ≤2, patients will be enrolled in a 1:1 randomization to receive treatment with either the novel SCB balloon or the comparative PCB balloon. The balloon sizing will be selected according to the lumen-based approach derived from optical coherence tomography (OCT). The primary endpoint is 6-month mean net lumen diameter gain (6-month minimum lumen diameter [MLD] minus baseline MLD) assessed by quantitative coronary analysis (QCA) with non-inferiority margin of 0.3 mm in per-protocol analysis. The clinical follow-up will be conducted up to 1 year. The enrollment started in September 2020 and will complete in April 2021. CONCLUSIONS: The TRANSFORM I trial will assess the efficacy of novel SCB in terms of non-inferiority to conventional PCB with a novel OCT measurement approach in patients with a de-novo SVD. Clinical Trial Registration URL: https://clinicaltrials.gov. Unique identifier: NCT03913832.
Asunto(s)
Angioplastia Coronaria con Balón , Fármacos Cardiovasculares , Enfermedad de la Arteria Coronaria , Angiografía Coronaria , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Enfermedad de la Arteria Coronaria/terapia , Humanos , Paclitaxel , Estudios Prospectivos , Sirolimus , Resultado del TratamientoRESUMEN
AIMS: The aim of this study was to evaluate the biological efficacy of a novel lower-dose (2.5 µg/mm2) encapsulated paclitaxel nanocrystal-coated balloon (Nano-PCB) in the familial hypercholesterolaemic swine (FHS) model of iliofemoral in-stent restenosis. METHODS AND RESULTS: Nano-PCB pharmacokinetics were assessed in 20 femoral arteries (domestic swine). Biological efficacy was evaluated in ten FHS: 14 days following bare metal stent implantation each stent segment was randomised to a clinically available PCB (IN.PACT, n=14), the Nano-PCB (n=14) or an uncoated balloon (n=12). Angiographic, optical coherence tomography and histological evaluation was performed at 28 days after treatment. Arterial paclitaxel concentration was 120.7 ng/mg at one hour and 7.65 ng/mg of tissue at 28 days with the Nano-PCB. Compared to the control uncoated group, both PCBs significantly reduced percent area stenosis (Nano-PCB: 36.0±14.2%, IN.PACT: 29.3±9.2% vs control: 67.9±15.1%, p<0.001). Neointimal distribution in the entire stent length was more homogenous in the Nano-PCB. Histological evaluation showed comparable degrees of neointimal proliferation in both PCBs; however, the Nano-PCB showed slightly higher levels of neointimal maturity and endothelialisation. CONCLUSIONS: Lower-dose encapsulated paclitaxel nanocrystals delivered via a coated balloon displayed comparable biological efficacy with superior healing features compared to a clinically validated PCB technology.
Asunto(s)
Antineoplásicos/farmacología , Arteria Femoral/efectos de los fármacos , Oclusión de Injerto Vascular , Hiperlipoproteinemia Tipo II , Arteria Ilíaca/efectos de los fármacos , Paclitaxel/farmacología , Stents , Cicatrización de Heridas/efectos de los fármacos , Angiografía , Angioplastia Coronaria con Balón/instrumentación , Animales , Antineoplásicos/administración & dosificación , Modelos Animales de Enfermedad , Arteria Femoral/diagnóstico por imagen , Arteria Femoral/patología , Arteria Femoral/cirugía , Arteria Ilíaca/diagnóstico por imagen , Arteria Ilíaca/patología , Arteria Ilíaca/cirugía , Metales , Nanopartículas/administración & dosificación , Neointima , Paclitaxel/administración & dosificación , Enfermedades Vasculares Periféricas , Sus scrofa , Porcinos , Tomografía de Coherencia ÓpticaRESUMEN
Treatment of unprotected left main (ULM) in-stent restenosis (ISR) in patients with prior drug eluting stent implantation is challenging. Treatment usually involves complex stenting procedures or bypass grafting. Drug coated balloon (DCB) is relatively new concept which is usually used in treatment of ISR. In a patient of ULM ISR, use of DCBs is a safe, economic and a technically simple option with relatively good outcomes. We report use of simultaneous kissing balloon dilatation with novel sirolimus coated balloons (SCBs) via radial artery to treat ULM ISR.
RESUMEN
BACKGROUND: Second generation of drug eluting stents (DES) has attempted to improve safety using abluminal sirolimus drug delivery with biodegradable polymers matrix. The present preclinical study was designed to investigate the safety and efficacy profile of Abluminus™ stents (SES). This is a new coronary stent with sirolimus and biodegradable polymer matrix coated on abluminal stent and balloon surface. METHODS: SES were compared with two controls: bare metal stent (BMS) and BMS + polymer coated stents (PC). All devices (40 stents) were implanted in porcine coronary arteries with primary endpoint of endothelialization at 7 days and subsequent histological and morphometric evaluations at 7, 30 and 90 days. RESULTS: Early endothelialization at seven days was complete in all stents. Histology at 30 days revealed minimum inflammation in all groups and increased at 90 days in PC group while it was absent at 180 days. Thirty day morphometry showed significantly reduction of neointimal area in Abluminus™ (SES 0.96±0.48 mm(2); BMS 1.83±0.34 mm(2); PC 1.76±0.55 mm(2); P<0.05); after 90 days neointimal area was 1.10±0.54 mm(2) for SES; 1.92±0.36 mm(2) for BMS; and 1.94±0.48 mm(2) for PC; P<0.05). Neointimal thickness at 30 and 90 days respectively was 0.15±0.07 and 0.18±0.10 mm for SES, 0.57±0.08 and 0.61±0.09 mm for BMS and 0.52±0.09 and 0.59±0.08 mm, P<0.001 for PC group. CONCLUSIONS: The most significant experimental evidence appears to be earlier endothelialization at 7 days for SES which led to safety of the device. Efficacy of the device was also observed by a reduced neointimal thickness and minimized inflammatory score at all follow-ups. Termination of antiplatelet at 30 days has not shown any further complications. Polymer thickness was almost in negligible amount at 180 days with no inflammation.
RESUMEN
BACKGROUND: Permanent polymers in first generation drug-eluting stent (DES) have been imputed to be a possible cause of persistent inflammation, remodeling, malapposition and late stent thrombosis. We aim to describe the in vivo experimental result of a new polymer-free DES eluting sirolimus from stent-plus-balloon (Focus np stent, Envision Scientific) compared with a bare-metal stent (BMS) (Amazonia CroCo, Minvasys) and with a biolimus A9 eluting stent (Biomatrix, Biosensors). METHODS: In 10 juvenile pigs, 23 coronary stents were implanted in the coronary arteries (8 Amazonia CroCo, 8 Focus np, and 7 Biomatrix). At 28-day follow-up, optical coherence tomography (OCT) and histology were used to evaluate neointimal hyperplasia and healing response. RESULTS: According to OCT analysis, Focus np stents had a greater lumen area and less neointimal hyperplasia response than BMS and Biomatrix had. Histomorphometry results showed less neointimal hyperplasia in Focus np than in BMS. Histology showed a higher fibrin deposition in Biomatrix stent compared to Focus np and BMS. CONCLUSIONS: The new polymer-free DES with sirolimus eluted from stent-plus-balloon demonstrated safety and reduced neointimal proliferation compared with the BMS and Biomatrix stents at 28-day follow-up in this porcine coronary model. This new polymer-free DES is promising and warrants further clinical studies.
RESUMEN
Drug-eluting stents have proven to be effective in reducing the risk of late restenosis. In order to achieve a controlled and prolonged release of the antiproliferative agent, current drug-eluting stents utilise various biodegradable as well as non-erodible polymeric blends to coat the stent surface and to serve as drug carriers. The utilisation of polymeric compounds in current drug-eluting stents may eventually limit their performance as well as their clinical applicability due to the potential induction of undesirable local reactions. The development of alternative, polymer-free drug carriers has the potential to overcome some of the limitations of current drug-eluting stent formulations. Moreover, improvements in drug carriers may also result in an expansion of the technological possibilities for other intravascular drug delivery systems, such as metal-free or even implant-free solutions. This article describes the structure and the preclinical validation profile of a novel phospholipid encapsulated sirolimus nanocarrier, used as a coating in two formulations: a coronary stent-plus-balloon system and a stand-alone balloon catheter. The nanoparticles provided a stable, even and homogenous coating to the devices in both formulations. Dose-finding studies allowed the most appropriate identification of the best nanoparticle structure associated with an extremely efficient transfer of drug to all layers of the vessel wall, achieving high tissue concentrations that persisted days after the application, with low systemic drug leaks.
Asunto(s)
Angioplastia de Balón/instrumentación , Fármacos Cardiovasculares/administración & dosificación , Catéteres , Materiales Biocompatibles Revestidos , Portadores de Fármacos , Stents Liberadores de Fármacos , Nanopartículas , Fosfolípidos/química , Sirolimus/administración & dosificación , Animales , Fármacos Cardiovasculares/sangre , Fármacos Cardiovasculares/química , Fármacos Cardiovasculares/farmacocinética , Preparaciones de Acción Retardada , Modelos Animales de Enfermedad , Arteria Femoral/lesiones , Arteria Femoral/metabolismo , Arteria Ilíaca/lesiones , Arteria Ilíaca/metabolismo , Cinética , Masculino , Conejos , Sirolimus/sangre , Sirolimus/química , Sirolimus/farmacocinética , Porcinos , Distribución Tisular , Lesiones del Sistema Vascular/sangre , Lesiones del Sistema Vascular/patología , Lesiones del Sistema Vascular/terapiaRESUMEN
BACKGROUND: Norovirus is a single-stranded RNA virus belonging to the Caliciviridae family. METHODS: Our observational cohort study aimed to describe a nosocomial outbreak of norovirus on a bone marrow transplant (BMT) unit. RESULTS: Six of 8 BMT patients with increased liquid stools tested positive for norovirus: 4 had new onset diarrhea; 2 had acute exacerbations of chronic diarrhea caused by graft versus host disease. Eight non-BMT inpatients had norovirus infection, but 7 of these were community acquired; cumulative incidence rates in BMT and non-BMT units were 26% and 0.16%, respectively. In BMT patients, diarrhea (increased or new onset) lasted 6 to 33 days-durations shorter than those reported in sporadic BMT cases. All patients had private rooms and bathrooms. Five of 6 patients were on the BMT unit during their presumed incubation periods. Three were in adjacent rooms. Three nurses and 1 physician had symptoms compatible with norovirus infection, and all 4 worked while ill. The outbreak ended coincident with implementation of stricter infection control practices. CONCLUSION: Norovirus appeared to spread in a BMT unit more avidly than it did among general medical patients. Explanations include prolonged diarrhea and viral excretion, long hospital stays of infected patients, rarity of empiric contact isolation for diarrhea, routine handling of liquid stool, and a closed community of health care workers.
Asunto(s)
Infecciones por Caliciviridae/epidemiología , Brotes de Enfermedades , Gastroenteritis/epidemiología , Norovirus/aislamiento & purificación , Adulto , Trasplante de Médula Ósea , Estudios de Cohortes , Femenino , Gastroenteritis/virología , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Introdução: Magic TouchTM é um balão recoberto com nanopartículas carreadoras de sirolimus. Objetivamos encontrar a dose excipiente: fármaco com a maior capacidade de inibição da proliferação neointimal 28 dias após o uso desse balão pós-implante de stent não-farmacológico em artérias coronárias porcinas. Métodos: Foram avaliados 14 porcos com implante coronário de stent não-farmacológico seguido por dilatação(60 segundos) com balões com relação excipiente: sirolimus 1:1, 0,5:1, 0,25:1 e 1:0 ou balão controle. Após 28 dias a hiperplasia neointimal foi estudada por tomografia de coerência óptica e histopatologia. Resultados: A hiperplasia neointimal porcentual (%) avaliada pela tomografia de coerência óptica e pela histomorfometria foi de 32,2 e 35,1, 28,1 e 33,4, 17,3 e20,9, 28,6 e 30,2, e 37,9 e 42,3 nos grupos excipiente: sirolimus 0,25:1, 0,5:1, 1:1, 1:0 e balão controle, respectivamente (P = 0,03 para excipiente: sirolimus 1:1 vs. balão controle). A espessura (mm) da neoíntima inter-hastes foi de 0,23, 0,30, 0,16, 0,24 e 0,30 nos grupos excipiente: sirolimus 0,25:1,0,5:1, 1:1, 1:0 e balão controle, respectivamente (P < 0,01para excipiente: sirolimus 1:1 vs. balão controle). Os escores de inflamação, injúria e deposição de fibrina foram baixos e sem diferenças significantes entre os grupos. Conclusões: Ocorreu gradual aumento da eficácia inibitória da proliferação neointimal à medida que a concentração do excipiente aumentou; amenor eficácia ocorreu com a formulação excipiente: sirolimus 0,25:1 e a mais intensa inibição foi observada com a formulação excipiente: sirolimus 1:1, a qual reduziu significantemente a proliferação neointimal em comparação com o grupo controle, com baixos índices de inflamação e injúria.